Core Insights - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in ETFs, commodities, technology, and pharmaceutical sectors [1] - The company emphasizes a conservative investment approach, aiming to deliver substantial returns and strategic insights to clients [1] - Allka Research is committed to simplifying investment strategies, making them accessible to both seasoned and novice investors [1] Company Mission - The mission of Allka Research is to empower individuals financially by sharing knowledge and insights through the Seeking Alpha platform [1] - The company aims to provide thought-provoking analyses and informed perspectives to foster a community of informed investors [1] - Allka Research seeks to demystify investing, inspiring confidence in readers to navigate the financial markets intelligently [1]

Core Viewpoint - In the event of a recession, it is expected that individuals will continue to take their prescriptions and will not cancel major medical treatments, indicating resilience in the healthcare sector [1] Group 1 - The healthcare industry is likely to remain stable during economic downturns as essential medical needs persist [1]

Core Insights - The "High-Income DIY Portfolios" Marketplace service aims to provide high income with low risk and capital preservation for DIY investors, particularly targeting income investors such as retirees or near-retirees [1][2] - The service offers a total of 10 model portfolios, including 3 buy-and-hold, 3 rotational portfolios, and a conservative NPP strategy portfolio, designed to create stable, long-term passive income with sustainable yields [1][2] Group 1 - The service includes two High-Income portfolios, two Dividend Growth Investing (DGI) portfolios, and a conservative NPP strategy portfolio that focuses on low drawdowns and high growth [1] - The unique 3-basket investment approach aims for 30% lower drawdowns, 6% current income, and market-beating growth over the long term [2] - The portfolios are structured to cater to varying levels of risk and include buy and sell alerts along with live chat support for investors [2]

Group 1 - Walmart (WMT) will be added to the Nasdaq-100 Index on January 20, 2026, replacing AstraZeneca (AZN) [3] - The Nasdaq-100 Index includes 100 of the largest non-financial companies, indicating Walmart's significant market position [3]

Macro Dynamics - The National Internet Information Office has drafted regulations for the collection and use of personal information by internet applications, aiming to protect personal information rights and promote reasonable use [2] - The regulations require apps to request necessary personal information only when users are using specific functions and to inform users of the purpose of data collection [2] Market Regulation - The State Administration for Market Regulation has revised the "Complaint and Reporting Handling Measures" to enhance consumer rights protection and regulate malicious claims [3] - Key revisions include strengthening rights protection, optimizing complaint jurisdiction, improving reporting procedures, and preventing abuse of the system [3] Market Data - On January 9, US stock indices closed higher, with the Dow Jones and S&P 500 reaching all-time closing highs [7] - Intel saw a significant increase of over 10%, marking its largest single-day gain since September, while Tesla and Meta also experienced gains [7] Company Dynamics - Walmart will be included in the Nasdaq-100 Index on January 20, 2026, replacing AstraZeneca [9] - OpenAI and SoftBank announced a joint investment of $1 billion in SB Energy, part of the "Stargate" initiative, with plans for a 1.2GW data center in Texas [10]

Core Viewpoint - Walmart is set to join the Nasdaq-100 Index, replacing AstraZeneca, effective January 20 [1] Group 1: Index Inclusion - Walmart will also join the Nasdaq-100 Equal Weighted Index and the Nasdaq-100 Ex-Tech Sector Index [1] Group 2: Strategic Moves - Companies often switch exchanges for better alignment with investor bases and services [1] Group 3: Nasdaq-100 Characteristics - The Nasdaq-100 is known for including top non-financial companies [1]

Core Viewpoint - Walmart Inc will be added to the Nasdaq 100 Index, replacing AstraZeneca Plc, with the change effective before the market opens on January 20 [1] Group 1: Walmart's Market Position - Walmart's market value has approached nearly $1 trillion, driven by steady sales growth and share gains as consumers favor lower-priced essentials [4] - The company has expanded its digital operations, with its US e-commerce business expected to achieve profitability this year, alongside growth in advertising, marketplace, and membership revenue [4] - Walmart shares have increased by 146% on a total return basis over the past three years [5] Group 2: Index Impact and Inflows - Analysts from Jefferies Financial Group estimated that Walmart's inclusion in the Nasdaq 100 could lead to nearly $19 billion in inflows as index-tracking funds and exchange-traded products rebalance their holdings [2] - The Nasdaq 100 tracks the largest non-financial companies listed on the Nasdaq exchange, underpinning hundreds of billions of dollars in investment products, with over $600 billion in assets tracked through ETFs as of December 2025 [7] Group 3: AstraZeneca's Removal - AstraZeneca's removal from the Nasdaq 100 reflects a decline from its pandemic-era peak, primarily due to fading vaccine-related revenue and a shift in investor focus towards obesity treatments from competitors [6]

Group 1 - Walmart will replace AstraZeneca in the Nasdaq-100 Index starting January 20, 2026 [1] - This change reflects a significant shift in the index composition [1] - The announcement was made by Nasdaq [1]

Core Insights - Johnson & Johnson (JNJ) has signed a significant agreement with the Trump administration to lower drug prices in the U.S. [1] - JNJ is part of a broader trend among large-cap pharmaceutical companies committing to similar agreements to reduce drug prices [2] Agreement Details - Under the agreement, JNJ will reduce prescription drug prices to align with those in comparable developed countries, supporting the Most Favored Nation (MFN) pricing proposal [3] - JNJ will benefit from a limited-period exemption from import tariffs on pharmaceutical ingredients, contingent upon expanding its domestic manufacturing operations [4] Financial and Operational Impact - JNJ's shares have increased by 30.6% over the past six months, outperforming the industry growth of 20.4% [5] - The company is advancing a $55 billion plan to enhance U.S. manufacturing, research, and technology capabilities by early 2029 [6][7] - JNJ is constructing new facilities in Pennsylvania and North Carolina, including a $2 billion biologics plant expected to create approximately 5,000 jobs [8] Industry Trends - Other large-cap pharmaceutical companies are also investing significantly in U.S.-based manufacturing and R&D, with AstraZeneca committing $50 billion by 2030 and AbbVie planning over $10 billion by 2035 [9][10][13] - Lilly has announced a $27 billion investment to develop new manufacturing sites, enhancing production capacity for its marketed drugs [14]

Core Viewpoint - The announcement highlights the collaboration between the company's subsidiary, Huyou Haiyue, and AstraZeneca to conduct clinical trials for HYP-6589 in combination with Osimertinib for treating specific types of non-small cell lung cancer [1] Group 1: Company Developments - Huyou Haiyue has developed HYP-6589, a highly selective SOS1 small molecule inhibitor, which is currently in the clinical trial phase [1] - The collaboration with AstraZeneca involves a clinical trial agreement to study the safety, tolerability, pharmacokinetics, and efficacy of HYP-6589 both as a monotherapy and in combination with Osimertinib [1] Group 2: Industry Context - Osimertinib, marketed as Tagrisso, is a third-generation oral epidermal growth factor receptor tyrosine kinase inhibitor developed by AstraZeneca, already approved in China for specific non-small cell lung cancer treatments [1] - The partnership aims to explore innovative treatment options in the oncology sector, particularly for non-small cell lung cancer, which remains a significant area of focus in cancer research [1]